Dr. Mark Perkins, Chief Scientific Officer of FIND, said "We are pleased at the progress that GBD is making in developing their technology..."
Geneva, Switzerland (PRWEB) December 18, 2011
FIND (Foundation for Innovative New Diagnostics), a Geneva-based not-for-profit, and Global BioDiagnostics Corp. (GBD), a US-based biotechnology company commercializing potentially breakthrough technology to diagnose tuberculosis (TB), announced an extension of their Phase 1 Co-Development Agreement aimed at developing a rapid, low-cost and simple test for the detection of active TB in a Point-of-Care (POC) setting.
"It is a great benefit to continue to work with FIND as we strive to bring such a needed test to the TB diagnostics market. Their support is crucial to developing a POC test that truly meets the needs of affected populations,” said Michael T. Norman, JD, CEO of Global BioDiagnostics Corp. “Along with their financial support, having been so successful at bringing innovative new products to the TB market, they are an invaluable advisor for our efforts.”
Dr. Mark Perkins, Chief Scientific Officer of FIND, said "We are pleased at the progress that GBD is making in developing their technology in a way that is consistent with the mission of FIND, which is to bring diagnostics to the market that are affordable, accurate and suitable for the particular needs of patients in high endemic countries."
- Tuberculosis (TB) is a contagious disease spread primarily by coughing.
- It is prevalent in developing countries, and up to a third of the world's population is infected;
- TB is one of the greatest threats to health worldwide, with nearly 9 million new cases and 2 million deaths a year due to the disease.
- The spread of TB has been exacerbated by (i) the large numbers of people from all over the world who travel; (ii) the worldwide rise of multi-drug resistance TB strains; and (iii) the global spread of HIV, with markedly increases susceptibility to TB;
- The lack of simple diagnostics that can be used at the community level to rapidly detect tuberculosis and interrupt transmission is one of the primary obstacles to disease control;
- Sputum microscopy, currently the most widely used method to detect TB, is cumbersome and insensitive, leaving many patients undetected. Bacterial culture is more sensitive, but takes 4-6 weeks to complete, and is too complex for most settings where TB patients are seen;
- The HIV pandemic has led to a resurgence of TB as a major public health problem. Immunodeficient HIV-positive patients are particularly vulnerable to TB, which is responsible for the deaths of at least 40 per cent of patients in this group.
FIND is dedicated solely to developing affordable, easy-to-use and cutting edge diagnostic tests that save lives in the poorest areas of the world. From the initial idea and discovery stage to putting new tests into practice, the organization works with multiple and diverse groups, from academia, industry, donors, partners in the field, Ministries of Health and the World Health Organization. With five new diagnostic tools for TB already in use, FIND also has programs in malaria and sleeping sickness. Launched in 2003, the not-for-profit Foundation, with an established ISO-certified project management framework, has headquarters in Geneva and offices in Kampala, Uganda, and New Delhi, India. FIND is financed by both the private and public sectors. Donors currently include the Bill & Melinda Gates Foundation, Government of the Netherlands, the German Ministry of Education and Research, the European Union, UNITAID, UK Department for International Development, National Institutes of Health (USA) and others. For more information, please visit http://www.finddiagnostics.org, or contact Dr. Mark Perkins at mark(dot)perkins(at)finddiagnostics(dot)org.
About Global BioDiagnostics Corp.:
Global BioDiagnostics Corp. is a biotechnology company whose mission is to develop, manufacture and distribute diagnostics that address huge needs in the global infectious disease market. The company’s products in development for TB utilize a ground-breaking biophotonic detection platform developed by researchers at Texas A&M Health Science Center College of Medicine, Texas A&M University and Stanford University. The research conducted by Texas A&M was funded by the Bill and Melinda Gates Foundation and the funding for Stanford was through a sub-grant by Texas A&M. The company has offices in Temple, Texas and Daresbury, England. For more information, please visit http://www.gbdbio.com, or contact Michael T. Norman at mnorman(at)gbdbio(dot)com.